Bibliography
- Morris J, Twaddle S. Anorexia nervosa. BMJ 2007;334:894-8
- Steinglass JE, Eisen JL, Attia E, et al. Is anorexia nervosa a delusional disorder? An assessment of eating beliefs in anorexia nervosa. J Psychiatr Pract 2007;13:65-71
- Stein KF, Corte C. Identity impairment and eating disorders: content and organization of the self-concept in women with anorexia nervosa and bulimia nervosa. Eur Eat Disord Rev 2007;15:58-69
- Bachner-Melman R, Zohar AH, Ebstein RP, Bachar E. The relationship between selfssness levels and the severity of anorexia nervosa symptomatology. Eur Eat Disord Rev 2007;15:213-20
- Uher R, Murphy T, Brammer MJ, et al. Medial prefrontal cortex activity associated with symptom provocation in eating disorders. Am J Psychiatry 2004;161:1238-46
- Fassino S, Pieró A, Daga GA, et al. Attentional biases and frontal functioning in anorexia nervosa. Int J Eat Disord 2002;31:274-83
- Kojima S, Nagai N, Nakabeppu Y, et al. Comparison of regional cerebral blood flow in patients with anorexia nervosa before and after weight gain. Psychiatry Res 2005;140:251-8
- Braun CM, Chouinard MJ. Is anorexia nervosa a neuropsychological disease? Neuropsychol Rev 1992;3:171-212
- Attia E, Walsh BT. Anorexia nervosa. Am J Psychiatry 2007;164:1805-10
- Spindler A, Milos G. Links between eating disorder symptom severity and psychiatric comorbidity. Eat Behav 2007;8:364-73
- Wildes JE, Marcus MD, Gaskill JA, Ringham R. Depressive and manic-hypomanic spectrum psychopathology in patients with anorexia nervosa. Compr Psychiatry 2007;48:413-18
- Powers PS, Bannon Y, Eubanks R, McCormick T. Quetiapine in anorexia nervosa patients: an open labeled outpatient pilot study. Int J Eat Disord 2007;40:21-6
- Brambilla F, Garcia CS, Fassino S, et al. Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol 2007;22:197-204
- Fassino S, Lanfranco F, Abbate Daga G, et al. Prolonged treatment with glycerophosphocholine, an acetylcholine precursor, does not disclose the potentiating effect of cholinesterase inhibitors on GHRH-induced somatrotroph secretion in anorexia nervosa. J Endocrinol Invest 2003;26:503-7
- Mancini A, Valle D, Conte G, et al. Pre- and postprandial pyridostigmine and oxiracetam effects on growth hormone secretion in anorexia nervosa. Psychoneuroendocrinology 1996;21:621-9
- Bonner LT, Peskind ER. Pharmacologic treatment of dementia. Med Clin North Am 2002;86:657-74
- Burt T, Sachs GS, Demopulos C. Donepezil in treatment-resistant bipolar disorder. Biol Psychiatry 1999;45:959-64
- Román GC, Rogers SJ. Donepezil: a clinical review of current and emerging indications. Expert Opin Pharmacother 2004;5:161-80
- Chen X, Magnotta VA, Duff K, et al. Donepezil effects on cerebral blood flow in older adults with mild cognitive deficits. J Neuropsychiatry Clin Neurosci 2006;18:178-85
- Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescent with autistic disorder. J Child Adolesc Psychopharmacol 2002;12:237-41
- Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003;11:131-45
- Anand R, Hartman R, Sohn H, et al. Impact of study design and patient population on outcomes from cholinesterase inhibitor trials. Am J Geriatr Psychiatry 2003;11:160-8
- Seltzer B. Donepezil: an update. Expert Opin Pharmacother 2007;8:1011-23
- Akaike A. Preclinical evidence of neuroprotection by cholinesterase inhibitors. Alzheimer Dis Assoc Disord 2006;20:S8-11
- Racchi M, Mazzucchelli M, Porrello E, et al. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 2004;50:441-51
- Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics of cholinesterase inhibitors. Clin Pharmacokinet 2002;41:719-39